Panagora Asset Management’s Seres Therapeutics MCRB Stock Holding History

Panagora Asset Management’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-8,354	Closed	-$1.07M	–	1484
2022 Q3	$1.07M	Buy	8,354 +627	+8%	+$64.2K	0.01%	830
2022 Q2	$530K	Buy	7,727 +3,667	+90%	+$316K	﹤0.01%	1145
2022 Q1	$578K	Hold	4,060	–	–	﹤0.01%	1159
2021 Q4	$676K	Buy	+4,060	New	+$645K	﹤0.01%	1088
2021 Q2	–	Sell	-2,647	Closed	-$1.09M	–	2885
2021 Q1	$1.09M	Buy	2,647 +2,636	+23,964%	+$1.21M	0.01%	989
2020 Q4	$5K	Buy	+11	New	+$6.44K	﹤0.01%	2465
2017 Q3	–	Sell	-260	Closed	-$59K	–	2427
2017 Q2	$59K	Hold	260	–	–	﹤0.01%	2024
2017 Q1	$59K	Buy	260 +43	+20%	+$8.73K	﹤0.01%	1982
2016 Q4	$43K	Hold	217	–	–	﹤0.01%	2120
2016 Q3	$53K	Buy	+217	New	+$76.1K	﹤0.01%	2103

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Panagora Asset Management's MCRB Position: Q4 2022 in Review

Panagora Asset Management sold out of Seres Therapeutics (MCRB) in Q4 2022, closing a stake of 8,354 shares — an estimated $1.07M sold.

Panagora Asset Management first reported a position in MCRB in Q3 2016 and held it in 10 quarters. The position peaked at $1.09M in Q1 2021. 123 funds tracked by Wall St. Rank hold MCRB as of Q4 2022.

Panagora Asset Management reported no remaining Seres Therapeutics position as of Q4 2022 after selling out during the quarter.
Panagora Asset Management sold 8,354 Seres Therapeutics shares in Q4 2022, an estimated $1.07M.
Panagora Asset Management first reported a position in Seres Therapeutics in Q3 2016 and held it in 10 quarters.
Panagora Asset Management's Seres Therapeutics position peaked at $1.09M in Q1 2021.
123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2022.

Based on Panagora Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.